| To medicate or not to medicate, when diagnosis is in question: decision-making in first episode psychosis. | |
| | |
MedLine Citation:
|
PMID: 20158435 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: This paper reports on a brief survey of clinicians' judgements when making treatment decisions in the context of diagnostic uncertainty. Specifically, attitudes and opinions were sought from practising consultant psychiatrists regarding two key areas of clinical decision-making in first episode psychosis (FEP), namely, when to initiate medication and, how long to continue treatment. METHOD: Interviews were conducted with consultant psychiatrists using a combination of structured and semi-structured questions that examined and explored pharmacological treatment decisions in FEP. RESULTS: Twenty-three consultant psychiatrists participated in the interviews. The threshold to initiate pharmacological treatment was lower when a risk to self or others is present, when symptoms are primarily positive, when the patient is in distress, or where there is a family history of mental illness. Atypical antipsychotics are routinely used as front-line medication in FEP and the choice of medication is determined largely by their likely side effect profile. However, the greater the perceived efficacy, the greater the anticipated tolerability burden. The ideal duration of treatment is considered to be 1-2 years in instances of full remission, and 5 years where only a partial response has been achieved or where recovery has not been sustained. CONCLUSIONS: The 'first episode' represents a unique period in the management of psychosis where by definition there is no history of pattern of illness, diagnostic certainty is rare, and the patient usually does not have any prior exposure to medications. Therefore, each management decision needs to be considered following a risk benefit analysis which takes into account the context of the individual. |
| | |
Authors:
|
Gin Malhi; Danielle Adams; Beverley Moss; Garry Walter |
Related Documents
:
|
20740095 - Interview with lawrence weed, md- the father of the problem-oriented medical record loo... 20609095 - Economic evaluation in clinical nephrology: part 1. an introduction to conducting an ec... 2755735 - When parents demand treatment. 3425975 - From whom the bell tolls: the emerging decision-makers for life-support systems in choi... 18426615 - Safety and efficacy of beta agonists. 3773485 - Sudden death due to ingestion of cocaine. |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists Volume: 18 ISSN: 1440-1665 ISO Abbreviation: Australas Psychiatry Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-20 Completed Date: 2010-08-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9613603 Medline TA: Australas Psychiatry Country: England |
Other Details:
|
Languages: eng Pagination: 230-7 Citation Subset: IM |
Affiliation:
|
Department of Academic Psychiatry, CADE Clinic, Royal North Shore Hospital, NSW, Australia. gmalhi@med.usyd.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antipsychotic Agents
/
therapeutic use* Attitude of Health Personnel Dangerous Behavior Decision Trees Genetic Predisposition to Disease Humans Interview, Psychological Judgment* Male Marijuana Abuse / complications, psychology Pain Measurement Psychoses, Substance-Induced / diagnosis, drug therapy, psychology Psychotic Disorders / diagnosis*, drug therapy*, genetics, psychology Referral and Consultation* Risk Assessment Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Time to 'get real': preliminary insights into the long-term management of schizophrenia.
Next Document: Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders.